Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    OncoCyte Corporation

    NASDAQ: OCX · Real-Time Price · USD
    2.67
    -0.03 (-1.11%)
    At close: Jun 13, 2025, 3:59 PM
    2.65
    -0.75%
    After-hours: Jun 13, 2025, 04:04 PM EDT

    OncoCyte Statistics

    Share Statistics

    OncoCyte has 28.6M shares outstanding. The number of shares has increased by 113.99% in one year.

    Shares Outstanding

    n/a
    		 28.6M

    Shares Change (YoY)

    n/a
    		 113.99%

    Shares Change (QoQ)

    n/a
    		 69.88%

    Owned by Institutions (%)

    n/a
    		 0.34%

    Shares Floating

    n/a
    		 20.06M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,205

    FTD / Avg. Volume

    n/a
    		 2.57%

    Short Selling Information

    The latest short interest is 265.49K, so 0.93% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 265.49K

    Short % of Shares Out

    n/a
    		 0.93%

    Short % of Float

    n/a
    		 1.97%

    Short Ratio (days to cover)

    n/a
    		 7.76

    Valuation Ratios

    The PE ratio is -0.51 and the forward PE ratio is -2.81. OncoCyte's PEG ratio is -0.02.

    PE Ratio

    n/a
    		 -0.51

    Forward PE

    n/a
    		 -2.81

    PS Ratio

    n/a
    		 16.54

    Forward PS

    n/a
    		 5.8

    PB Ratio

    n/a
    		 -2.53

    P/FCF Ratio

    n/a
    		 -1.47

    PEG Ratio

    n/a
    		 -0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for OncoCyte.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.62, with a Debt / Equity ratio of -0.3.

    Current Ratio

    n/a
    		 1.62

    Quick Ratio

    n/a
    		 1.56

    Debt / Equity

    n/a
    		 -0.3

    Debt / EBITDA

    n/a
    		 -0.06

    Debt / FCF

    n/a
    		 -0.17

    Interest Coverage

    n/a
    		 -726.68

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $40,891.3

    Profits Per Employee

    n/a
    		 $-1,318,760.87

    Employee Count

    n/a
    		 46

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 2.78

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -1.1% in the last 52 weeks. The beta is 0.99, so OncoCyte's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.99

    52-Week Price Change

    n/a
    		 -1.1%

    50-Day Moving Average

    n/a
    		 2.97

    200-Day Moving Average

    n/a
    		 2.82

    Relative Strength Index (RSI)

    n/a
    		 39.05

    Average Volume (20 Days)

    n/a
    		 46,869

    Income Statement

    In the last 12 months, OncoCyte had revenue of 1.88M and earned -60.66M in profits. Earnings per share was -4.66.

    Revenue

    n/a
    		 1.88M

    Gross Profit

    n/a
    		 740K

    Operating Income

    n/a
    		 -61.04M

    Net Income

    n/a
    		 -60.66M

    EBITDA

    n/a
    		 -59.02M

    EBIT

    n/a
    		 -60.58M

    Earnings Per Share (EPS)

    n/a
    		 -4.66
    Full Income Statement

    Balance Sheet

    The company has 8.64M in cash and 3.66M in debt, giving a net cash position of 4.97M.

    Cash & Cash Equivalents

    n/a
    		 8.64M

    Total Debt

    n/a
    		 3.66M

    Net Cash

    n/a
    		 4.97M

    Retained Earnings

    n/a
    		 -350.54M

    Total Assets

    n/a
    		 60.36M

    Working Capital

    n/a
    		 26.58M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -20.71M and capital expenditures -516K, giving a free cash flow of -21.23M.

    Operating Cash Flow

    n/a
    		 -20.71M

    Capital Expenditures

    n/a
    		 -516K

    Free Cash Flow

    n/a
    		 -21.23M

    FCF Per Share

    n/a
    		 -1.62
    Full Cash Flow Statement

    Margins

    Gross margin is 39.34%, with operating and profit margins of -3245.14% and -3225.04%.

    Gross Margin

    n/a
    		 39.34%

    Operating Margin

    n/a
    		 -3245.14%

    Pretax Margin

    n/a
    		 -3225.04%

    Profit Margin

    n/a
    		 -3225.04%

    EBITDA Margin

    n/a
    		 -3137.43%

    EBIT Margin

    n/a
    		 -3245.14%

    FCF Margin

    n/a
    		 -1128.6%

    Dividends & Yields

    OCX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for OCX is $4.25, which is 57.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $4.25

    Price Target Difference

    n/a
    		 57.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jul 25, 2023. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 Jul 25, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -9.78

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist